Primary Objective~Determine the composite complete remission (CR) and complete remission with incomplete peripheral blood recovery (CRi) rates, safety and tolerability in patients under 22 years of age with SMN treated with one or two courses of CPX-351 before HSCT.~Secondary Objectives~Describe the toxicity profile of patients with SMN treated with one or two courses of CPX-351.~Describe the biologic correlates of response in patients with SMN after one or two courses of CPX-351.~Estimate the 3-year overall survival of patients who received one or two courses of CPX-351 followed by HSCT.~Participants who meet the inclusion criteria and consent will receive up to 2 cycles of CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice.
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).